Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Bill, I also have contacted Mark several times and he always responds promptly. The last time, a couple of weeks ago, he told me that the spin-off was going great and that the S-1 would be filed "soon", just as he has told a few other posters in the yahoo MB. I don't know what "soon" means to him ...weeks, months?... the dictionary says it means "in the near future" and "shortly" another word Mark likes to use..not a precise measurement of time.
When you contacted him last weeks did he say anything other than "soon" for the S-1. Also did the power point presentation mention the diagnostic tests or only the instruments side of the house.
I also have recommended ARYC to a few of relatives and friends and although they are interested in the tests being developed, they are skeptical of penny stocks because of their poor track record. ARYC's share price has fluctuated so much that I'm glad they did not buy in March when the price was 0.40 only to see it go down to 0.15. I still think there is a lot of upside potential for this stock, and have bought some more, but the lack of guidance from the company does not inspire confidence for the general investor population.
Good find Dr_C.
In the PDF file where they list the Presenting Companies, they list AD as
"Arrayit Diagnostics, Inc. Private Going Public"
That's a good sign, the spin-off is still happening.
Seeking more investors has been part of their spin-off plan.
In their press releases Arrayit has mentioned that John would be focusing "on the approval process with the FDA and establishing strategic relationships for marketing of the test" and that this "pure play in diagnostics will enhance AD’s ability to attract investors and the licensing partners necessary to fulfill our mission of creating the diagnostic tools required to significantly impact oncology."
Also, to participate in the event they have to meet this criteria
Minimum Criteria for Pre-Public Companies
- Disruptive, but proven technologies, products or services
- Demonstrating positive revenue growth
- Potential to create new markets and/or gain significant market share within a visible time-frame
- Experienced leadership
- Definitive plan to become publicly listed within the next 12-18 months
About the event:
Wall Street 1-2-1 has pioneered an innovative approach to bringing together – in one place and at one time – up to 100 of the nation’s leading professional investment firms with the corporate executives from up to 100 high growth public and pre-public companies to achieve their respective investment-screening and market exposure objectives.
Hosted at a world class resort destination, each Wall Street 1-2-1 event features a series of fast-paced “Meet the Money” sessions. During these highly energized meeting sessions, corporate managers have the opportunity to give brief, high impact presentations – on a one to one basis -- to each of the invited investment firms. Think speed-dating – only better!
Each five minute presentation is strictly timed and limited to ten or fewer PowerPoint slides in flipchart form. By virtue of this efficient presentation format, investors are able to rapidly assess which of the presenting companies are of interest to them and merit further due diligence and/or a 30-minute ‘second date’ on the final day of the event.
You ask "Why is Arrayit and AD seeming not pushing OvaDx out to the public more?"
I asked Arrayit last year a similar question, and they answered that they are concentrating first and foremost in getting the science right. And that once the product is in clinical use it will get much publicity.
I personally think that they need to publish studies about OvaDx in scientific journals for the medical industry and the public to review and get familiar with OvaDx.
OvaDx with sensitivity approaching 90% and specificity approaching 100% will qualify as a screening test. Since 100% specificity means 0% false positives it is a home run for Arrayit. No other diagnostic test (for any disease) in the market has 0 false positives. OvPlex has 94% specificity meaning 6% false positives. 6% may be acceptable for women with symptoms, but never as a screening test. Were OvPlex to be used for screenig, 6% false positives would mean 150 surgeries to find 1 ovarian cancer.
The problem with Arrayit is that they keep most of OvaDx information too close to their vest. Very few people outside of Arrayit know the particulars about the test, so no organization is going to give them an award until the details are out and their studies are published.
I wish they had given us an update of the spinoff in the 10Q
I wish they had given us an update of the spinoff in the 10Q
Ovplex is for symptomatic women...not for screening.
Any idea of when the S-1 will be filed?
I believe the bloodcards are a fantastic product, and they should make a lot of money for ARYC. If you don't me asking, what are you going to do with it?
Plus all existing common shares, of course.
We posted around the same time. LOL. The filing should calm the shorts posting on Yahoo MB
10k filed for FY 2011
News release today. Good news. Great OvaDx(R) research study results.
SUNNYVALE, Calif., April 4, 2012 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTCBB:ARYC) and Arrayit Diagnostics, Inc. ("AD") report significant results from a 257 patient research study on its pre-symptomatic ovarian cancer molecular diagnostic test in development, OvaDx(R). In this study, OvaDx(R) recorded sensitivity of 79.7%, correctly identifying patients known to have cancer, and specificity approaching 100%, correctly identifying the healthy controls, patients known not to have cancer.
Since July of 2009, AD has operated as an independent subsidiary of Arrayit Corporation and holds all the intellectual property, licenses and development agreement assets related to the pre-symptomatic ovarian cancer diagnostic test known as OvaDx(R). On December 14th, 2011, Arrayit Corporation announced the spin-off of AD and the distribution of its 78.18% interest in AD as a stock dividend to ARYC shareholders. The record date, dividend distribution date and further details will be announced shortly.
"We continue to make additional enhancements subsequent to this pilot study that indicate improvements in the sensitivity number approaching 90%. We are working to make this diagnostic test superior to any existing test. Requiring only a finger stick of blood, this will also be the easiest test to administer," says Dr. Mark Schena, President and Chief Scientific Officer of Arrayit Corporation.
About Arrayit Corporation
Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. Please visit www.arrayit.com for more information.
About Arrayit Diagnostics
Arrayit Diagnostics, headquartered in Redmond, Oregon, is leading the research and approval process of the pre-symptomatic ovarian cancer test, OvaDx(R), based on molecular diagnostic technology.
Safe Harbor Statement
We have identified forward-looking statements by using words such as "expect," "believe," and "should." Although we believe our expectations are reasonable, our operations involve a number of risks and uncertainties that are beyond our control, and these statements may turn out not to be true. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-KA for the fiscal year ended December 31, 2011 and Form 10-Q for the quarter ended September 30, 2011.
.
.
Contact:.
.
Investor RelationsArrayit CorporationTel: 408-744-1331 Email: investorinfo@arrayit.comWeb: www.arrayit.com
Yes I think that a PR is coming soon with more details.
Did you learn anything new about the spin-off?
I hope you're right. If the "FDA" Trials for the first half of 2012 are related to post market studies, then that would mean that FDA approval is at hand.
Additional thoughts about your scenario and figures. We don't know yet how they will structure the deal with the AD partner. Of the 650.00 that they may charge for OvaDx test, the partner will get a cut of that. Let's say it's 50%. That will mean 325.00 per test revenue for AD and ARYC combined. So in the 1,000,000 yearly example ARYC+AD get 325,000,000 revenue.
AD has around 25 million shares outstanding.
For ARYC we don't know yet how many common shares will be outstanding on the 30th. It depends on how many warrants and options get executed and how many preferred stocks get converted to common before the 30th. You may end up with around 40 million ARYC common stock.
So you have really 65 million ARYC + AD shares.
Using you 5X multiple, 325 mill X 5= 1.65 billion revenue
If you divide the 1.65 billion revenue revenue evenly by 65 million shares you get $25 per each ARYC share and $25 per each AD share. Still life changing values and I would be happy if that was the pps.
This is a plausible scenario Dr_C6. One piece of the puzzle that is kind of odd is that Howell said that they are planning to do "FDA trials" in the first half of this year. Were those trials additional ones requested by the FDA while processing the PMA application, or are they being done prior to a PMA submission.?
Somebody wants to drive the pps down so that they can buy cheaper, so that somebody most likely sold 130 shares at 0.32 to create a downward motion. I don't think that game it's going to work this time. Investors are securing their ARYC positions to get the dividend, and are not going to sell cheap now.
supposed to come out mid-February...as we know they are not too good at forecasting dates ...LOL
You articulated the same interpretations I have. Their PRs are always vague and seem to raise more questions than they anwswer. Hopefully they will give an interview to the press and flesh out the details.
I don't think the PR answered too many questions. They say the record date is "expected" to be occur by March 30. So we don't have an exact date yet, only an expectation. Everything else in the PR is stuff we already knew, except for the mention of a potential Nasdaq listing.
The first trade at 9:30 was 10k shares @ 0.49
After that the ASK kept dropping all the way to 0.38 at the close. It seems to me a seller is working on pushing the price down.
When they announce the record date and spin-off date, they will also file the Prospectus for the Diagnostics spin-off. The Prospectus should have information and status about OvaDx so that anyone planning to buy the Diagnostics stock knows what the company is all about. And at the same time they may announce the household name strategic investor they hinted at in the genoweb article. When all these fireworks happen, I expect ARYC pps to make a quantum leap.
Arrayit posted an ammended 10K for Dec 31, 2010 today at the SEC. I could not figure out what changed from the one they filed last April.
Are they out?
Bid for Illumina may spark additional deals as companies race to bring DNA scanning into routine medical use.
"General Electric Co. and Abbott as companies with existing businesses that may consider a similar acquisition"
Roche's Illumina Bid May Spur Buying in DNA Test Land Grab Business Week Jan 26
Less than 10 years after the first human genome was decoded, Roche Holding AG's hostile $5.7 billion bid for Illumina Inc. may spark additional deals as companies race to bring DNA scanning into routine medical use.
Illumina competes with Life Technologies Corp., Affymetrix Inc. and other companies to sell gene-decoding machines that are just starting to be used to tailor therapies for patients with cancer and inherited diseases. While scientific excitement around genome sequencing is high, the companies' shares have plummeted over the last year because their target customers are mostly scientists dependent on grants in a tough economy.
Getting the technology out of the lab and into doctors' offices and hospitals could vastly expand the existing $1.5 billion market for gene sequencing machines, industry officials and analysts said.
“This is going to be an enormous opportunity, and now you see it unfolding,” said Greg Lucier, chief executive officer of Life Technologies, based in Carlsbad, California, in a telephone interview. The bid Roche is an acknowledgment that DNA mapping is key to the future of diagnostics, particularly involving its use in cancer treatment, he said.
More text of the story can be read at:
http://news.businessweek.com/article.asp?documentKey=1376-LYDKOX07SXKX01-04EHKFCTVQDF5UO2I5P8KLBKK5
I don't think Rene's presentation has much to do with the recent rise. There is excitment in the investment community becaue of the impending spin-off of ARYC diagnostics, and also because the 5.7 Billion bid by Roche to buy Illumina. ARYC and ILMN share many similarities in the genetic testing space. Attention is being drawn to this field that has taken off in the last 10 years.
Good catch! Change to OvaDx® Ovarian Cancer Diagnostic Test from RUO made this week in their website is indeed very interesting. They are really getting ready now!
"Patient samples should be shipped on dry ice or room temperature for blood cards according to the instructions provided above. A diagnostic report for each patient sample is included with each test. Diagnostic test results are to be used in accordance of all local, state and federal regulations including those set forth by the United States Food and Drug Administration (FDA)."
"Arrayit Diagnostics, Inc. OvaDx® Large Panel Ovarian Cancer Diagnostic Test has been developed for diagnostic purposes and will be sold for clinical applications upon FDA approval."
The 10K is a long way coming. It is not due until 3/30/2012. ARYC will probably then ask for an extension until 4/15 like they did last year. But we should be getting other announcements before then regarding the spin-off, investors, partnerships and hopefully Ovadx. And of course the spin-off dividend shares.
Check out new article about spin-off in yahoo
message board post
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_A/threadview?m=tm&bn=124026&tid=1494&mid=1494&tof=1&frt=2
Good article about spin-offs. It ties in nicely with the strategy that Howell and Schena spelled out in genomeb article on January 8. 2010...see post in yahoo message board on this subject
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_A/threadview?m=te&bn=124026&tid=1479&mid=1485&tof=1&frt=2#1485
MabCure Announces Completion of Its Ovarian Cancer Diagnostic Study in Thailand
Data Analysis Expected to be Completed in Six Months
Press Release: MabCure, Inc. – Thu, Dec 15, 2011 2:09 PM EST
http://finance.yahoo.com/news/MabCure-Inc-Announces-bw-1598504181.html?x=0
Wow. Our cheerleader Dr. C is going sour on the company. Now I'm worried.
food for thought ... and from what I read somewhere he had no prior experience in the Diagnostics industry before 2009 when he became CEO of Arrayit DIagnostics.
The one thing I'm concerned about is the CEO of Arrayit Diagnostics. Is he really top notch to run a public company?
At the bottom of the PR they have a new contact for Investors relations:
Arrayit Corporation
Celeste Wade, 408-744-1331
Investor Relations
investorinfo@arrayit.com
Rene Schena will be in video promoting Sunnyvale
FOR IMMEDIATE RELEASE
Sunnyvale, California, United States of America (Free-Press-Release.com) December 4, 2011 --
With pharmaceutical companies like Pfizer Inc. investing in shifting operations to a few bioscience hotspots (Wall Street Journal, November 23, 2011), Sunnyvale, CA, in the heart of Silicon Valley, is betting that a testimonial by successful CEO Rene Schena of Arrayit Corporation, will seal the deal. Sunnyvale is currently home to Lockheed Martin, Yahoo, Network Appliance, Northrop Grumman Marine, Molecular Devices, Intuitive Surgical, St. Jude Medical, and research organizations such as the Parkinson’s Institute and NASA Ames Space Science Research Center. Google is opening a campus in Sunnyvale in 2012. Indeed, Sunnyvale was the #1 top rated City throughout North and South America for “Best Economic Potential” this year, according to Financial Times “American Cities of the Future 2011/12” report. Sunnyvale also topped the list of “25 Most Inventive Cities” in the nation with more patents per capita than any other as ranked by TheDailyBeast.com, a merger of the Daily Beast & Newsweek.
“Rene Schena, CEO of Arrayit Corporation, demonstrates leadership, determination and the ability to project success through a business with fantastic potential,” said the Sunnyvale Economic Development spokesperson. Arrayit provides products to researchers and institutions and OEM products for multi-billion dollar corporations around the world and in its own backyard of Sunnyvale. As CEO, Ms. Schena was rated #11th “Largest Woman Owned Business” in 2005 by the Silicon Valley Business Journal and as a private company, twice achieved status as the “Fastest Growing” Biotech Company in America by Inc. Magazine’s the Inc.500. Now publicly traded, Arrayit is benefiting from its credibility on the lab-bench, offering novel proprietary products manufactured in Sunnyvale in instrumentation, products and services for the life science, research and diagnostic industries. Under Rene Schena's stewardship, Arrayit's patented gene and protein printing technologies have the lead the microarray field since its inception. Arrayit's discoveries in microarray applications have now led the company beyond research tools and instrumentation into the clinical diagnostics arena as it continues to develop its OvaDx cancer diagnostic.
The video documentary produced by the City of Sunnyvale will be available in January 2012
MabCure Receives U$500,000.00 Licensing Fee as Well as 12.5% Ongoing Royalty for Its Prostate Cancer Diagnostic Technology
Nov 22 2011 NEW YORK--(BUSINESS WIRE)-- MabCure, Inc. (OTCBB: MBCI.OB - News), a leading developer of antibody-based diagnostics and treatments for ovarian and prostate cancer, today announced that it has signed a license agreement with Biotech Investment Corp. (“Biotech”), a Nevada-based biotechnology investment company. The agreement is an exclusive worldwide license to certain MabCure hybridoma clones producing antibodies against prostate cancer. In addition to the license fee paid to MabCure, Biotech will issue to MabCure 15% of its outstanding shares on a fully diluted basis and will pay a royalty of 12.5% on revenues.
The need for a new method for diagnosing prostate cancer has become evident recently due to the major controversy over the usefulness of PSA testing. PSA is a marker of inflammation of the prostate, not of prostate cancer, and, as such, it is not surprising that repeated clinical studies have shown that PSA testing fails to alter the survival rate of prostate cancer patients. MabCure’s antibodies are aimed at prostate cancer markers and as such may have the potential for yielding an accurate diagnosis of prostate cancer.
Dr. Amnon Gonenne, CEO of MabCure, commented: “This is a very exciting deal for MabCure and its shareholders. It demonstrates the confidence of our investors (Biotech) in our technology and the early proof of concept attained with our antibodies for the diagnosis of ovarian cancer. The license fee will mainly be used to further the development and testing of our hybridoma clones for the diagnosis of Ovarian Cancer. We look forward to working with Biotech on developing the prostate cancer diagnostic test and are excited about the parallel development and testing of our antibodies for the detection and treatment of two forms of cancer.”
Thanks for posting this. It's very educational.